High Mobility Group Box 1 Gene Polymorphism and Serum High Mobility Group Box 1, Interleukin 1 Beta, and Alpha-Klotho

Maha Houssen1, Rasha El-Mahdy2, Nouran E Samra2

  • 1Biochemistry Department, Faculty of Pharmacy, Damanhour University, Damnhour, Egypt.

PubMed

Insights

Serum levels of HMGB1, IL1β, and α-klotho are elevated in critically ill COVID-19 patients. These biomarkers, along with HMGB1 rs1045411 polymorphism, may indicate disease severity and offer therapeutic targets.

Area of Science:

  • Biochemistry
  • Immunology
  • Genetics

Background:

  • COVID-19 severity varies, necessitating biomarkers for prognosis.
  • HMGB1, IL1β, and α-klotho are implicated in inflammatory and cellular processes.

Purpose of the Study:

  • Evaluate serum HMGB1, IL1β, and α-klotho in COVID-19 patients across severity spectrums.
  • Correlate these markers with clinicopathological parameters.
  • Assess HMGB1 rs1045411 polymorphism and its association with COVID-19 severity.

Main Methods:

  • Serum samples from 120 COVID-19 patients and 80 controls were analyzed.
  • HMGB1, IL1β, and α-klotho levels measured using ELISA.
  • HMGB1 rs1045411 polymorphism genotyped via RT-PCR.

Main Results:

  • Significantly higher serum HMGB1, IL1β, and α-klotho in critically ill COVID-19 patients.
  • HMGB1 rs1045411 polymorphism showed decreased T/T genotype frequency in patients versus controls.
  • ROC analysis indicated moderate diagnostic utility for these serum markers.

Conclusions:

  • Serum HMGB1, IL1β, and α-klotho may serve as indicators of COVID-19 severity.
  • These biomarkers represent potential therapeutic targets for COVID-19 management.
Abstract